The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
Objective: This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar. Methods: All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1–7, 8–14, 15–21, 22–28, and <28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period. Results: A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during 15–21, 22–28, and <28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7–93.3% lower during the corresponding time periods (P < 0.001 for each). Conclusion: The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 108(2021), Seite 116-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmed Zaqout [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BNT162b2 |
|---|
| doi: |
10.1016/j.ijid.2021.05.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ071964606 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ071964606 | ||
| 003 | DE-627 | ||
| 005 | 20230503064304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.05.021 |2 doi | |
| 035 | |a (DE-627)DOAJ071964606 | ||
| 035 | |a (DE-599)DOAJb3788b78edd64d04b41569210f0c6d23 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Ahmed Zaqout |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar. Methods: All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1–7, 8–14, 15–21, 22–28, and <28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period. Results: A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during 15–21, 22–28, and <28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7–93.3% lower during the corresponding time periods (P < 0.001 for each). Conclusion: The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a mRNA | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Joanne Daghfal |e verfasserin |4 aut | |
| 700 | 0 | |a Israa Alaqad |e verfasserin |4 aut | |
| 700 | 0 | |a Saleh A.N. Hussein |e verfasserin |4 aut | |
| 700 | 0 | |a Abdullah Aldushain |e verfasserin |4 aut | |
| 700 | 0 | |a Muna A. Almaslamani |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammed Abukhattab |e verfasserin |4 aut | |
| 700 | 0 | |a Ali S. Omrani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 108(2021), Seite 116-118 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2021 |g pages:116-118 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.05.021 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b3788b78edd64d04b41569210f0c6d23 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221004227 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2021 |h 116-118 | ||